First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial
A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.
Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM
Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC
A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.
Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy
A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.